Proactive Investors - Run By Investors For Investors

Danish drugs giant Novo Nordisk to use e-Therapeutics’ technology in search for new diabetes treatments

e-Therapeutics will be reimbursed for its work under this collaboration and Novo Nordisk has the option to license relevant IP generated under the collaboration
Novo Nordisk is predominantly focused on diabetes

The world’s largest producer of insulin is to use e-Therapeutics PLC’s (LON:ETX) Network-Driven Drug Discovery (NDD) platform as it looks to discover new ways of treating type-2 diabetes.

Type-2 diabetes primarily occurs as a result of lack of exercise and obesity and is thought to account for around 90% of the 425mln people with diabetes around the world.

Scientists have been tasked with finding new treatments in order to tackle the growing incidence of the condition.

READ: ETX and C4X team up to find new Parkinson’s treatments

As part of the tie-up, Danish pharma giant Novo Nordisk will use ETX’s NDD approach to identify novel intervention strategies, biological pathways and compounds for testing that could potentially form the basis of novel therapies.

e-Therapeutics will be reimbursed for its work under this collaboration and Novo Nordisk has the option to license relevant IP generated under the collaboration.

Any future license would require mutual agreement of commercial terms. Financial details of the collaboration have not been disclosed.

 “We are delighted to be working with Novo Nordisk, a world leader and innovator in diabetes care,” said ETX chief executive Ray Barlow.

“This collaboration highlights the use of our Network-Driven Drug Discovery (NDD) platform to understand and potentially create new treatments for complex diseases of great relevance to society, medicine and the industry.”

“Our new collaboration with Novo Nordisk is the result of a systematic and rigorous business development exercise over the past year and we hope to announce a number of additional collaborations during the course of 2019.”

Novo Nordisk’s head of bioinformatics, Jan Nygaard Jensen, added: “We are looking forward to cooperating with e-therapeutics. It is an exciting technology and we will investigate if it can support some of the early target discovery efforts we are building in Novo Nordisk Research Center Oxford.”

View full ETX profile View Profile

e-Therapeutics plc Timeline

Research Video
March 28 2018

Related Articles

technician's in a lab clean-room
March 12 2019
The Maryland company is seeing revenue surge through an expansion of contract manufacturing services, particularly in the area of CAR T-cell therapies
February 22 2019
The company is developing drugs for blood disorders, metabolic diseases and curbing alcohol use
May 30 2019
The Toronto-based company’s leading products are Rasuvo and Metoject, a unique formulation of methotrexate that is designed to treat rheumatoid arthritis and other auto-immune diseases
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use